EA202092320A1 - Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли - Google Patents

Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли

Info

Publication number
EA202092320A1
EA202092320A1 EA202092320A EA202092320A EA202092320A1 EA 202092320 A1 EA202092320 A1 EA 202092320A1 EA 202092320 A EA202092320 A EA 202092320A EA 202092320 A EA202092320 A EA 202092320A EA 202092320 A1 EA202092320 A1 EA 202092320A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
heterobicyclic
malignant tumor
mat2a inhibitors
Prior art date
Application number
EA202092320A
Other languages
English (en)
Inventor
Зинон Д. Контитис
Минцзун Ли
Пэн ЛЮ
Мэттью Медейрос
Сэмьюэл К. Резник
Чжихуа Суй
Джереми М. Трэвинс
Джанета Поповичи-Мюллер
Шубао Чжоу
Гуаннин Ма
Original Assignee
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аджиос Фармасьютикалз, Инк. filed Critical Аджиос Фармасьютикалз, Инк.
Publication of EA202092320A1 publication Critical patent/EA202092320A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Настоящее изобретение относится к соединениям в соответствии с формулой (I) или формулой (II) и их фармацевтически приемлемым солям, стереоизомерам и/или таутомерам, описанным в настоящем изобретении. Также предложены фармацевтические композиции и способы применения соединений для лечения злокачественных опухолей, включая некоторые злокачественные опухоли, у которых делетирован ген, кодирующий метилтиоаденозин-фосфорилазу (МТАР).
EA202092320A 2018-03-30 2019-03-28 Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли EA202092320A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018081328 2018-03-30
PCT/US2019/024645 WO2019191470A1 (en) 2018-03-30 2019-03-28 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
EA202092320A1 true EA202092320A1 (ru) 2021-03-09

Family

ID=67439309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092320A EA202092320A1 (ru) 2018-03-30 2019-03-28 Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли

Country Status (18)

Country Link
US (1) US11524960B2 (ru)
EP (1) EP3774805B1 (ru)
JP (2) JP7350005B2 (ru)
KR (1) KR20200138769A (ru)
CN (1) CN111936499B (ru)
AR (1) AR115326A1 (ru)
AU (1) AU2019243289B2 (ru)
BR (1) BR112020020104A2 (ru)
CA (1) CA3094476A1 (ru)
EA (1) EA202092320A1 (ru)
IL (1) IL277665B2 (ru)
MA (1) MA52232A (ru)
MX (1) MX2020010005A (ru)
PH (1) PH12020551507A1 (ru)
SG (1) SG11202009195WA (ru)
TW (1) TWI719437B (ru)
UA (1) UA127059C2 (ru)
WO (1) WO2019191470A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105469YA (en) 2018-12-10 2021-06-29 Ideaya Biosciences Inc 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2020139991A1 (en) * 2018-12-27 2020-07-02 Agios Pharmaceuticals, Inc. Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CA3124678A1 (en) * 2018-12-27 2020-07-02 Zenon D. Konteatis Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PE20220387A1 (es) * 2019-05-31 2022-03-18 Servier Lab Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer
WO2021252679A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
EP4165035A1 (en) * 2020-06-10 2023-04-19 Ideaya Biosciences, Inc. Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US20230227409A1 (en) * 2020-06-10 2023-07-20 Ideaya Biosciences, Inc. Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN115916778A (zh) * 2020-09-12 2023-04-04 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
JP2024502097A (ja) 2020-12-31 2024-01-17 南京再明医薬有限公司 三環式化合物とその用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022222911A1 (zh) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
WO2022253242A1 (zh) * 2021-06-02 2022-12-08 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
WO2023083210A1 (zh) * 2021-11-09 2023-05-19 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023125737A1 (en) * 2021-12-29 2023-07-06 Silexon Ai Technology Co., Ltd. Heterocyclic compounds and use thereof
TW202333696A (zh) * 2022-01-26 2023-09-01 大陸商勤浩醫藥(蘇州)有限公司 用於治療ｍｔａｐ缺失型癌症的甲硫氨酸腺苷轉移酶２ａ抑制劑
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
EA029273B1 (ru) * 2009-10-29 2018-03-30 Джиноско Киназные ингибиторы
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) * 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR20190075043A (ko) * 2016-07-05 2019-06-28 더 브로드 인스티튜트, 인코퍼레이티드 비시클릭 우레아 키나제 억제제 및 그의 용도
AU2017319500C1 (en) * 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Also Published As

Publication number Publication date
IL277665A (en) 2020-11-30
KR20200138769A (ko) 2020-12-10
CN111936499A (zh) 2020-11-13
TW201946629A (zh) 2019-12-16
UA127059C2 (uk) 2023-03-29
AU2019243289A1 (en) 2020-09-24
US11524960B2 (en) 2022-12-13
WO2019191470A1 (en) 2019-10-03
CN111936499B (zh) 2023-09-19
MX2020010005A (es) 2020-10-14
JP2023101762A (ja) 2023-07-21
BR112020020104A2 (pt) 2021-01-26
US20210115045A1 (en) 2021-04-22
JP7350005B2 (ja) 2023-09-25
EP3774805B1 (en) 2024-01-10
WO2019191470A8 (en) 2019-12-12
AR115326A1 (es) 2020-12-23
EP3774805A1 (en) 2021-02-17
SG11202009195WA (en) 2020-10-29
JP2021519783A (ja) 2021-08-12
TWI719437B (zh) 2021-02-21
AU2019243289B2 (en) 2023-01-12
PH12020551507A1 (en) 2021-09-13
CA3094476A1 (en) 2019-10-03
MA52232A (fr) 2021-02-17
IL277665B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2021009206A (es) Terapias contra el cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
EA201990219A2 (ru) Ингибиторы mek и способы их применения